Short description
Bio-Matrix Scientific Group is engaged in the research, design and development of regenerative medical applications.
Description
The focus of Regen BioPharma, Inc. is to developing translational medicine platforms for the rapid commercialization of stem cell therapies and to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the purpose of increased quality of life. Regen BioPharma has reviewed more than 20,000 US issued patents covering stem cell related subject matter, created a shortlist of 30 promising technologies for rapid commercialization, and currently is in negotiations to license several of these.
The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials), followed by exit. Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 1-2 years grows technologies from laboratory to an asset ready for spin-off or sale.
Last funding
Absolutely Noaccess
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
La Mesa, California, United States, North America
Founded on
January 1, 2005
Exited on
September 12, 2014
Went public on
September 12, 2014
Stock symbol
RGBP
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$34056 - 789030
Sign in for full access